June 1, 2023

AstraZeneca, the ambitious laboratory that has become Europe’s pet peeve

INVESTIGATION – The Anglo-Swedish group, associated with the University of Oxford, has accumulated setbacks and errors in the deployment of its vaccine. Caught in the middle of the political firing range of vaccine campaigns, he must restore confidence.

Dunkirk, January 20, 2020. Emmanuel Macron and Pascal Soriot visit the AstraZeneca factory, where the laboratory has just announced an investment of 450 million euros. The President of the Republic celebrates the attractiveness of France; the French boss of the Anglo-Swedish giant relishes his popularity in his company and in his native country. On that day, the coronavirus was still only a very distant echo of a very Chinese problem. The iron curtain of containment will not fall on Wuhan until two days later. Neither Emmanuel Macron nor Pascal Soriot has a presentiment that they are preparing to face the most terrible of crises. That the first will soon have to confine France, once, twice, and maybe three. That the second will soon want to save the world, and manufacture three billion doses of vaccine. That their paths to both will soon be linked, for better or for worse.

A year and two months later, Pascal Soriot “Is in the hot seat and he knows it perfectly”.

This article is for subscribers only. You have 96% left to discover.

Subscribe: 1 € the first month

Can be canceled at any time

Already subscribed? Log in


Leave a Reply

Your email address will not be published. Required fields are marked *